{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:15:44Z","timestamp":1763968544229,"version":"build-2065373602"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasitology International"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.parint.2023.102845","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T11:50:41Z","timestamp":1702468241000},"page":"102845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immune tolerance caused by repeated P. falciparum infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism"],"prefix":"10.1016","volume":"99","author":[{"given":"Nirianne Marie Q.","family":"Palacpac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken J.","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Arisue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tougan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Horii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"World Health Organization","key":"10.1016\/j.parint.2023.102845_bb0005"},{"author":"Geddes","key":"10.1016\/j.parint.2023.102845_bb0010"},{"issue":"9","key":"10.1016\/j.parint.2023.102845_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40267-022-00937-3","article-title":"RTS,S\/AS01 malaria vaccine (Mosquirix\u00ae): a profile of its use","volume":"38","author":"Syed","year":"2022","journal-title":"Drugs Ther Perspect."},{"issue":"12","key":"10.1016\/j.parint.2023.102845_bb0020","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: a phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"10387","key":"10.1016\/j.parint.2023.102845_bb0025","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(23)00902-9","article-title":"Gavi unveils malaria vaccine plans","volume":"401","author":"Zarocostas","year":"2023","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.parint.2023.102845_bb0030","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-year efficacy of RTS,S\/AS01 malaria vaccine among young African children","volume":"374","author":"Olotu","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parint.2023.102845_bb0035","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fimmu.2016.00463","article-title":"Malaria parasites: the great escape","volume":"7","author":"R\u00e9nia","year":"2016","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.parint.2023.102845_bb0040","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41590-018-0228-6","article-title":"Malaria prevention: from immunological concepts to effective vaccines and protective antibodies","volume":"19","author":"Cockburn","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.parint.2023.102845_bb0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.12688\/f1000research.22143.1","article-title":"Malaria vaccines: facing unknowns","volume":"9","author":"Palacpac","year":"2020","journal-title":"F1000Res."},{"issue":"10","key":"10.1016\/j.parint.2023.102845_bb0050","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.3390\/vaccines9101072","article-title":"Plasmodium falciparum malaria vaccines and vaccine adjuvants","volume":"9","author":"Bonam","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.parint.2023.102845_bb0055","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3390\/pathogens10101277","article-title":"Immunosuppression in malaria: do Plasmodium falciparum parasites hijack the host?","volume":"10","author":"Calle","year":"2021","journal-title":"Pathogens"},{"issue":"3","key":"10.1016\/j.parint.2023.102845_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017775","article-title":"Clues to evolution of the SERA multigene family in 18 Plasmodium species","volume":"6","author":"Arisue","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0065","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13071-020-04044-y","article-title":"Characteristic features of the SERA multigene family in the malaria parasite","volume":"13","author":"Arisue","year":"2020","journal-title":"Parasit. Vectors"},{"issue":"49","key":"10.1016\/j.parint.2023.102845_bb0070","doi-asserted-by":"crossref","first-page":"47524","DOI":"10.1074\/jbc.M206974200","article-title":"A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle","volume":"277","author":"Miller","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"49","key":"10.1016\/j.parint.2023.102845_bb0075","doi-asserted-by":"crossref","first-page":"47533","DOI":"10.1074\/jbc.M207145200","article-title":"Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth","volume":"277","author":"Aoki","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.parint.2023.102845_bb0080","doi-asserted-by":"crossref","first-page":"912","DOI":"10.4269\/ajtmh.2001.65.912","article-title":"Natural human immunoglobulin G subclass responses to Plasmodium falciparum serine repeat antigen in Uganda","volume":"65","author":"Okech","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"2","key":"10.1016\/j.parint.2023.102845_bb0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4269\/ajtmh.2006.74.191","article-title":"High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children","volume":"74","author":"Okech","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.parint.2023.102845_bb0090","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nchembio.70","article-title":"Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum","volume":"4","author":"Arastu-Kapur","year":"2008","journal-title":"Nat. Chem. Biol."},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030452","article-title":"Inhibitory potential of prodomain of Plasmodium falciparum protease serine repeat antigen 5 for asexual blood stages of parasite","volume":"7","author":"Alam","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.parint.2023.102845_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098460","article-title":"Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences","volume":"9","author":"Yagi","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.parint.2023.102845_bb0105","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.parint.2010.05.002","article-title":"Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36","volume":"59","author":"Horii","year":"2010","journal-title":"Parasitol. Int."},{"issue":"2","key":"10.1016\/j.parint.2023.102845_bb0110","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4161\/hv.22950","article-title":"TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36\/AHG malaria vaccine in nonhuman primate models","volume":"9","author":"Tougan","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.parint.2023.102845_bb0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.parint.2013.01.006","article-title":"Association of naturally acquired IgG antibodies against Plasmodium falciparum serine repeat antigen-5 with reduced placental parasitemia and normal birth weight in pregnant Ugandan women: a pilot study","volume":"62","author":"Owalla","year":"2013","journal-title":"Parasitol. Int."},{"issue":"5","key":"10.1016\/j.parint.2023.102845_bb0120","doi-asserted-by":"crossref","first-page":"724","DOI":"10.4269\/ajtmh.2006.74.724","article-title":"Pigmented monocytes are negative correlates of protection against severe and complicated malaria in Ugandan children","volume":"74","author":"Mujuzi","year":"2006","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"6","key":"10.1016\/j.parint.2023.102845_bb0125","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.vaccine.2017.01.001","article-title":"Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda","volume":"35","author":"Kanoi","year":"2017","journal-title":"Vaccine."},{"key":"10.1016\/j.parint.2023.102845_bb0130","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-3024.2009.01142.x","article-title":"Adjuvants for malaria vaccines","author":"Coler","year":"2009","journal-title":"Parasite Immunol."},{"issue":"9","key":"10.1016\/j.parint.2023.102845_bb0135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.ijpara.2021.01.006","article-title":"A review of combination adjuvants for malaria vaccines: a promising approach for vaccine development","volume":"51","author":"Pirahmadi","year":"2021","journal-title":"Int. J. Parasitol."},{"issue":"5","key":"10.1016\/j.parint.2023.102845_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064073","article-title":"Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36","volume":"8","author":"Palacpac","year":"2013","journal-title":"PLoS One"},{"issue":"46","key":"10.1016\/j.parint.2023.102845_bb0145","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1016\/j.vaccine.2020.09.056","article-title":"First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3)","volume":"38","author":"Ezoe","year":"2020","journal-title":"Vaccine."},{"key":"10.1016\/j.parint.2023.102845_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.978591","article-title":"Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children","volume":"13","author":"Bougouma","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0345","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1038\/s41598-018-23194-9","article-title":"Molecular camouflage of Plasmodium falciparum merozoites by binding of host vitronectin to P47 fragment of SERA5","volume":"8","author":"Tougan","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parint.2023.102845_bb0385","doi-asserted-by":"crossref","first-page":"1058081","DOI":"10.3389\/fcimb.2022.1058081","article-title":"African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination","volume":"12","author":"Arisue","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"5 Pt A","key":"10.1016\/j.parint.2023.102845_bb0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.parint.2016.06.012","article-title":"Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles","volume":"65","author":"Tougan","year":"2016","journal-title":"Parasitol. Int."},{"key":"10.1016\/j.parint.2023.102845_bb0160","doi-asserted-by":"crossref","first-page":"34363","DOI":"10.1038\/srep34363","article-title":"Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda","volume":"6","author":"Yagi","year":"2016","journal-title":"Sci. Rep."},{"year":"2001","author":"Janeway","series-title":"Immunobiology: The Immune System in Health and Disease","key":"10.1016\/j.parint.2023.102845_bb0165"},{"key":"10.1016\/j.parint.2023.102845_bb0170","doi-asserted-by":"crossref","first-page":"1119820","DOI":"10.3389\/fimmu.2023.1119820","article-title":"Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children","volume":"14","author":"Tiono","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.parint.2023.102845_bb0175","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (MosquirixTM): an overview","volume":"16","author":"Laurens","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.parint.2023.102845_bb0180","doi-asserted-by":"crossref","first-page":"1267372","DOI":"10.3389\/fimmu.2023.1267372","article-title":"Safety and immunogenicity of BK-SE36\/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double blinded, age de-escalation trial","volume":"14","author":"Ouedraogo","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.parint.2023.102845_bb0185","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/IAI.03069-14","article-title":"Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection","volume":"83","author":"Obiero","year":"2015","journal-title":"Infect. Immun."},{"key":"10.1016\/j.parint.2023.102845_bb0190","doi-asserted-by":"crossref","first-page":"1006716","DOI":"10.3389\/fimmu.2022.1006716","article-title":"Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacy","volume":"13","author":"Kc","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.parint.2023.102845_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009594","article-title":"PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection","volume":"17","author":"Murphy","year":"2021","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.parint.2023.102845_bb0200","doi-asserted-by":"crossref","DOI":"10.1111\/pim.12795","article-title":"Immune responses to malaria pre-erythrocytic stages: implications for vaccine development","volume":"43","author":"Abuga","year":"2021","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.parint.2023.102845_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.977472","article-title":"Five decades of clinical assessment of whole-sporozoite malaria vaccines","volume":"13","author":"Nunes-Caba\u00e7o","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.parint.2023.102845_bb0210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12916-022-02466-2","article-title":"Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children","volume":"20","author":"Feng","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.parint.2023.102845_bb0215","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/14760584.2016.1236689","article-title":"The RTS,S\/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination","volume":"15","author":"Vandoolaeghe","year":"2016","journal-title":"Expert Rev. Vaccines"},{"issue":"12","key":"10.1016\/j.parint.2023.102845_bb0220","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.parint.2023.102845_bb0225","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/21645515.2018.1560772","article-title":"Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi","volume":"16","author":"Khan","year":"2020","journal-title":"Hum Vaccin Immunother."},{"issue":"6","key":"10.1016\/j.parint.2023.102845_bb0230","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.4049\/jimmunol.179.6.4193","article-title":"The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum","volume":"179","author":"Bejon","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.parint.2023.102845_bb0235","doi-asserted-by":"crossref","first-page":"1058227","DOI":"10.3389\/fimmu.2022.1058227","article-title":"Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso","volume":"13","author":"Morter","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.parint.2023.102845_bb0240","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0264-410X(00)00036-0","article-title":"Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea","volume":"18","author":"Genton","year":"2000","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0245","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0264-410X(03)00536-X","article-title":"Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children","volume":"22","author":"Genton","year":"2003","journal-title":"Vaccine."},{"issue":"7","key":"10.1016\/j.parint.2023.102845_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pctr.0010034","article-title":"Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial","volume":"1","author":"Thera","year":"2006","journal-title":"PLoS Clin Trials."},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0255","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.vaccine.2005.11.037","article-title":"Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya","volume":"25","author":"Stoute","year":"2007","journal-title":"Vaccine."},{"issue":"14","key":"10.1016\/j.parint.2023.102845_bb0260","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.vaccine.2006.05.090","article-title":"Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa","volume":"25","author":"Sirima","year":"2007","journal-title":"Vaccine."},{"issue":"4","key":"10.1016\/j.parint.2023.102845_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/3221b8d9-038d-4e67-82fa-de6b1233b459","article-title":"Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12\u201324 months-old Burkinabe children, PLoS One. 4 (10) (2009) e7549. doi: 10.1371\/journal.pone.0007549. Erratum in","volume":"5","author":"Sirima","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.parint.2023.102845_bb0270","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/infdis\/jit185","article-title":"The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas","volume":"208","author":"Jepsen","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"38","key":"10.1016\/j.parint.2023.102845_bb0275","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","article-title":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","volume":"34","author":"Sirima","year":"2016","journal-title":"Vaccine."},{"issue":"10","key":"10.1016\/j.parint.2023.102845_bb0280","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.medj.2023.07.003","article-title":"Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults","volume":"4","author":"Silk","year":"2023","journal-title":"Med."},{"year":"2001","author":"Janeway","series-title":"Immunobiology: The Immune System in Health and Disease","key":"10.1016\/j.parint.2023.102845_bb0285"},{"key":"10.1016\/j.parint.2023.102845_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.702125","article-title":"Revisiting the mechanisms of immune evasion employed by human parasites","volume":"11","author":"Chulanetra","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"12","key":"10.1016\/j.parint.2023.102845_bb0295","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.4161\/hv.36134","article-title":"Immune camouflage: relevance to vaccines and human immunology","volume":"10","author":"De Groot","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.parint.2023.102845_bb0300","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017546","article-title":"Genome-wide identification of molecular mimicry candidates in parasites","volume":"6","author":"Ludin","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0305","doi-asserted-by":"crossref","first-page":"13872","DOI":"10.1038\/s41598-017-14351-7","article-title":"Host factors that modify Plasmodium falciparum adhesion to endothelial receptors","volume":"7","author":"Mahamar","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0925-4439(93)90122-H","article-title":"Multiple interactions between human vitronectin and Staphylococcus aureus","volume":"1225","author":"Liang","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.parint.2023.102845_bb0315","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1357-2725(99)00005-9","article-title":"Vitronectin","volume":"31","author":"Schvartz","year":"1999","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"4","key":"10.1016\/j.parint.2023.102845_bb0320","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1128\/MMBR.66.4.617-629.2002","article-title":"Helicobacter pylori interactions with host serum and extracellular matrix proteins: potential role in the infectious process","volume":"66","author":"Dubreuil","year":"2002","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"3","key":"10.1016\/j.parint.2023.102845_bb0325","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2958.2010.07373.x","article-title":"Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion","volume":"78","author":"Singh","year":"2010","journal-title":"Mol. Microbiol."},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0330","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1160\/TH14-06-0561","article-title":"Binding of vitronectin and Factor H to Hic contributes to immune evasion of Streptococcus pneumoniae serotype 3","volume":"113","author":"Kohler","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"21","key":"10.1016\/j.parint.2023.102845_bb0335","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1002\/1873-3468.12351","article-title":"Host-pathogen interactions of nontypeable Haemophilus influenzae: from commensal to pathogen","volume":"590","author":"Duell","year":"2016","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147709","article-title":"Conserved patterns of microbial immune escape: pathogenic microbes of diverse origin target the human terminal complement inhibitor vitronectin via a single common motif","volume":"11","author":"Hallstr\u00f6m","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parint.2023.102845_bb0350","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12936-020-03229-1","article-title":"The malaria parasite Plasmodium falciparum in red blood cells selectively takes up serum proteins that affect host pathogenicity","volume":"19","author":"Tougan","year":"2020","journal-title":"Malar. J."},{"issue":"9","key":"10.1016\/j.parint.2023.102845_bb0355","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.vaccine.2011.12.124","article-title":"Geographic differentiation of polymorphism in the Plasmodium falciparum malaria vaccine candidate gene SERA5","volume":"30","author":"Tanabe","year":"2012","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.parint.2023.102845_bb0360","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.1997.6663","article-title":"The hemopexin-type repeats of human vitronectin are recognized by Streptococcus pyogenes","volume":"234","author":"Liang","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"16","key":"10.1016\/j.parint.2023.102845_bb0365","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/1873-3468.13772","article-title":"Complement in malaria: immune evasion strategies and role in protective immunity","volume":"594","author":"Kiyuka","year":"2020","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.parint.2023.102845_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003943","article-title":"Plasmodium falciparum erythrocyte invasion: combining function with immune evasion","volume":"10","author":"Wright","year":"2014","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.parint.2023.102845_bb0375","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0166-6851(97)00038-8","article-title":"Sequence diversity in the amino-terminal 47 kDa fragment of the Plasmodium falciparum serine repeat antigen","volume":"86","author":"Morimatsu","year":"1997","journal-title":"Mol. Biochem. Parasitol."},{"issue":"2","key":"10.1016\/j.parint.2023.102845_bb0380","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1383-5769(02)00088-0","article-title":"Sequence diversity in the amino-terminal region of the malaria-vaccine candidate serine repeat antigen in natural Plasmodium falciparum populations","volume":"52","author":"Safitri","year":"2003","journal-title":"Parasitol. Int."}],"container-title":["Parasitology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138357692300123X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138357692300123X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T10:38:28Z","timestamp":1761302308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138357692300123X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":77,"alternative-id":["S138357692300123X"],"URL":"https:\/\/doi.org\/10.1016\/j.parint.2023.102845","relation":{},"ISSN":["1383-5769"],"issn-type":[{"type":"print","value":"1383-5769"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune tolerance caused by repeated P. falciparum infection against SE36 malaria vaccine candidate antigen and the resulting limited polymorphism","name":"articletitle","label":"Article Title"},{"value":"Parasitology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parint.2023.102845","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102845"}}